ESSA Pharma Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- David Ross Parkinson
- Full Time Employees
- 35
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 999 West Broadway Vancouver BC Canada V5Z 1K5
- IPO Date
- Mar 13, 2015
- CIK
- 0001633932
- Website
- essapharma.com
- Similar Companies
- Business
- ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company focused on developing novel small molecule therapies targeting the androgen receptor for the treatment of prostate cancer; its lead candidate, masofaniten (formerly EPI-7386), is an oral N-terminal domain androgen receptor inhibitor in clinical development as a monotherapy for metastatic castration-resistant prostate cancer and in combination with antiandrogen treatments for patients earlier in the disease course. Founded in 2009 and headquartered at 999 West Broadway, Suite 720, Vancouver, British Columbia, the company previously advanced its proprietary aniten platform, including preclinical work on related compounds for prostate cancer and exploration of androgen receptor-driven tumors such as triple-negative breast cancer. In October 2025, ESSA completed its acquisition by XenoTherapeutics Inc., a Massachusetts-based non-profit biotechnology organization advancing xenotransplantation research, through a plan of arrangement under which ESSA shareholders received approximately $0.1242 per common share plus a contingent value right potentially worth up to $0.14 per share contingent on resolution of certain liabilities; the transaction followed an amended business combination agreement announced in September 2025 with XOMA Royalty Corporation acting as structuring agent and financier, leading to delisting from Nasdaq and a strategic shift from independent prostate cancer drug development operations.
ESSA Announces Completion of Arrangement with XenoTherapeutics
ESSA Securityholders Approve Acquisition by XenoTherapeutics
ESSA Pharma Inc. (EPIX) Shareholder/Analyst Call Prepared Remarks Transcript
ESSA Pharma Inc. Provides Update on its Application to the Supreme Court of British Columbia for Amended Interim Order
ESSA Pharma Inc. Amends Agreement with XenoTherapeutics
Essa Pharma Inc. to Adjourn Special Meeting to September 29, 2025
Essa Pharma Inc. Clarifies Nasdaq Due Bill Trading for Previously Announced Cash Distribution
Essa Pharma Inc. Announces Ex-Dividend Date and Nasdaq Due Bill Trading for Previously Announced Cash Distribution
Essa Pharma Inc. Announces US$80 Million Cash Distribution to Shareholders
ESSA Pharma Inc. Provides Update on its Application to the Supreme Court of British Columbia for Approval of an Interim Order and Cash Distribution to Shareholders
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of ESSA Pharma Inc. (NASDAQ: EPIX)
EPIX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of ESSA Pharma Inc. is Fair to Shareholders
ESSA Pharma Inc. Announces Definitive Agreement to be Acquired by XenoTherapeutics, Inc., Backed by XOMA Royalty Corporation in All-Cash Transaction
ESSA Pharma Reports Financial Results for Fiscal Second Quarter Ended March 31, 2025
Shareholders of ESSA Pharma Inc. Should Contact Levi & Korsinsky Before March 25, 2025 to Discuss Your Rights - EPIX
ESSA Pharma Inc. Class Action: Levi & Korsinsky Reminds ESSA Pharma Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 25, 2025 - EPIX
EPIX Deadline Today: Rosen Law Firm Urges ESSA Pharma Inc. (NASDAQ: EPIX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
ESSA Pharma Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 25, 2025 to Discuss Your Rights - EPIX
EPIX DEADLINE TODAY: ROSEN, LEADING INVESTOR COUNSEL, Encourages ESSA Pharma Inc. Investors to Secure Counsel Before Important March 25 Deadline in Securities Class Action - EPIX
Investors who lost money on ESSA Pharma Inc.(EPIX) should contact Levi & Korsinsky about pending Class Action - EPIX